Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score 6.00
- Grade Outperform
- Symbol (ABT)
- Company Abbott Laboratories
- Price $115.33
- Changes Percentage (-1.26%)
- Change -$1.47
- Day Low $114.54
- Day High $117.49
- Year High $121.64
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
- Last Earnings 09/19/2024
- Ex-Dividend for 5/16 Dividend 10/15/2024
- Dividend Payable 11/15/2024
- Today N/A
- Next Earnings (Estimated) 01/21/2025
- Fiscal Year End N/A
- Average Stock Price Target $128.00
- High Stock Price Target $150.00
- Low Stock Price Target $50.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.21
- Trailing P/E Ratio 33.51
- Forward P/E Ratio 33.51
- P/E Growth 33.51
- Net Income $5.72 B
Income Statement
Quarterly
Annual
Latest News of ABT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Abbott Laboratories (ABT) the Best Pharma Stock to Buy Right Now?
The article discusses the current status of Abbott Laboratories compared to other top pharma stocks. It highlights the growth in the pharmaceutical industry, advancements in medical technology, and th...
By Yahoo! Finance | 3 days ago -
Exploring High Growth Tech Stocks Including Beijing Labtech Instruments And 2 More
Global markets witnessed volatility with record highs followed by sharp declines, particularly impacting growth stocks. Amid this, small-cap stocks showed resilience, emphasizing the importance of foc...
By Yahoo! Finance | 4 days ago -
Decoding Abbott Laboratories (ABT): A Strategic SWOT Insight
Abbott Laboratories faces legal and regulatory hurdles impacting its operational landscape. Despite this, the company reported strong financial performance, with net earnings and comprehensive income ...
By Yahoo! Finance | 1 week ago
